US · HROW
Harrow Health, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Nashville, TN 37205
- Website
- harrowinc.com
Price · as of 2024-12-31
$40.90
Market cap 2.01B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $325.98 | +697.02% |
| Intrinsic Value(DCF) | $241.66 | +490.86% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $10.00 | ||||
| 2011 | $2.80 | ||||
| 2012 | $5.14 | ||||
| 2013 | $8.16 | $41.42 | $0.78 | $0.00 | $68.83 |
| 2014 | $8.00 | $2,461.10 | $0.14 | $0.00 | $0.00 |
| 2015 | $4.04 | $61.00 | $120,507.45 | $0.00 | $0.00 |
| 2016 | $2.47 | $33.91 | $438,878.74 | $0.00 | $0.00 |
| 2017 | $1.99 | $32.47 | $1,821.78 | $0.00 | $0.00 |
| 2018 | $6.56 | $119.94 | $652.02 | $4.36 | $40.27 |
| 2019 | $5.96 | $38.90 | $71.97 | $1.11 | $0.20 |
| 2020 | $8.22 | $172.00 | $7.66 | $0.39 | $0.00 |
| 2021 | $7.31 | $341.34 | $46.44 | $0.00 | $0.00 |
| 2022 | $17.64 | $51.37 | $0.61 | $0.00 | $0.00 |
| 2023 | $10.95 | $36.19 | $89.82 | $0.00 | $0.00 |
| 2024 | $24.38 | $325.98 | $228.94 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Harrow Health, Inc.'s (HROW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $325.98
- Current price
- $40.90
- AI upside
- +697.02%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$241.66
+490.86% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| HROW | Harrow Health, Inc. | $40.90 | 2.01B | +697% | +491% | — | — | -49.72 | 12.48 | 4.35 | 47.49 | — | -7.40 | 75.33% | 4.42% | -8.76% | -24.97% | 4.11% | -4.99% | 3.29 | 0.39 | 2.08 | 1.79 | 8.21 | -3467.00% | 5332.00% | -5906.00% | -7.00% | -0.24 | -28.36% | 0.00% | 0.00% | 0.00% | 119.11 | -17.26 | 5.26 | 1.98 |
| ALVO | Alvotech | $3.99 | 1.24B | +1,454% | +12% | — | — | -12.88 | -7.24 | 6.10 | -127.84 | — | -6.72 | 62.16% | 14.22% | -47.35% | 34.47% | 16.24% | -21.36% | -2.88 | 0.44 | 2.35 | 1.57 | -35.28 | -6420.00% | 43556.00% | -1807.00% | -9.84% | -1.22 | -68.51% | 0.00% | 0.00% | 0.00% | 59.25 | -14.04 | 8.43 | -0.85 |
| AMPH | Amphastar Pharmaceuticals… | $20.23 | 929.61M | +167% | -56% | -25% | -32% | — | 1.25 | 1.36 | 5.01 | — | 4.41 | 49.46% | 19.50% | 13.63% | 0.00% | 13.00% | 0.00% | 0.06 | 5.51 | 4.02 | 2.70 | -0.82 | -3366.00% | -165.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | — | 63.32% | 5.32 | — | 1.04 | 2.35 |
| BLFS | BioLife Solutions, Inc. | $24.20 | 1.17B | +49% | -55% | -73% | — | — | 2.89 | 11.18 | -103.07 | — | 2.89 | 64.56% | -12.61% | -12.61% | 0.00% | -4.52% | 0.00% | 0.03 | -4.48 | 5.23 | 5.23 | -1.18 | -4318.00% | 1697.00% | 28653.00% | 1.87% | 0.88 | 7.49% | 0.00% | — | 0.00% | -79.66 | 48.04 | 10.04 | 18.23 |
| COLL | Collegium Pharmaceutical,… | $41.67 | 1.32B | +93% | +451% | -64% | +46% | 20.98 | 4.37 | 1.69 | 4.41 | — | -2.57 | 59.35% | 23.01% | 8.05% | 23.70% | 14.73% | 3.79% | 2.70 | 2.18 | 1.57 | 1.36 | 1.47 | -699.00% | 2362.00% | 6111.00% | 24.84% | 0.75 | 39.58% | 0.00% | 0.00% | 17.45% | 9.73 | 5.33 | 2.24 | 1.51 |
| DVAX | Dynavax Technologies Corp… | $15.50 | 1.82B | +159% | -40% | -64% | -64% | 68.57 | 3.14 | 6.75 | 30.92 | — | 3.15 | 82.17% | -1.49% | 9.85% | 4.48% | -2.66% | 2.75% | 0.43 | -0.61 | 10.80 | 9.67 | 3.47 | -50323.00% | 1936.00% | -3763.00% | 3.21% | 0.85 | 43.90% | 0.00% | 0.00% | 5.34% | -342.86 | 23.49 | 5.10 | 2.81 |
| EVO | Evotec SE | $3.40 | 1.21B | +721% | -44% | — | — | -5.60 | 1.15 | 1.38 | -14.20 | -3.91 | 1.71 | 14.41% | -17.88% | -24.60% | -18.92% | -12.23% | -9.42% | 0.47 | -12.18 | 1.98 | 1.79 | -1.70 | 14348.00% | 199.00% | -3650.00% | -10.38% | 0.05 | -9.79% | 0.00% | 0.00% | 15.22% | -8.04 | -10.05 | 1.44 | 0.58 |
| KMTS | KESTRA MEDICAL TECHNOLOGI… | $23.28 | 1.36B | +67% | +283% | — | — | -6.49 | 3.60 | 12.35 | -5.57 | -4.28 | 3.60 | 40.47% | -177.85% | -190.28% | 5732.26% | 132.69% | -66.62% | 0.22 | -13.75 | 6.72 | 6.47 | 1.97 | 15147.00% | 11505.00% | 1941.00% | -13.70% | -2.04 | 126.23% | 0.22% | -1.50% | 31.39% | -5.13 | -5.39 | 9.12 | 2.34 |
| PHR | Phreesia, Inc. | $12.33 | 743.34M | +427% | +131% | — | — | -23.67 | 5.23 | 3.30 | -51.58 | — | 12.82 | 67.86% | -13.84% | -13.94% | -22.67% | -31.04% | -15.43% | 0.07 | -24.75 | 1.78 | 1.38 | 2.60 | -5936.00% | 1783.00% | -11443.00% | 0.60% | 0.28 | 4.43% | 0.00% | 0.00% | 0.00% | -22.71 | 159.09 | 3.14 | 4.70 |
| TLRY | Tilray Brands, Inc. | $7.87 | 796.82M | -67% | -67% | — | — | -0.19 | 0.28 | 0.51 | -0.23 | -0.03 | 0.57 | 29.29% | -277.93% | -266.25% | -88.71% | -84.34% | -68.11% | 0.22 | -55.23 | 2.46 | 1.35 | -0.05 | 65170.00% | 484.00% | 11348.00% | -30.24% | -0.34 | -4.97% | 0.00% | 0.00% | 12.04% | -0.22 | -3.87 | 0.60 | -5.74 |
| TRVI | Trevi Therapeutics, Inc. | $11.92 | 1.53B | — | — | — | — | -9.07 | 4.36 | — | -6.86 | -14.61 | 4.36 | 0.00% | — | — | -52.59% | 1707.29% | -47.84% | 0.01 | -12881.00 | 10.41 | 10.29 | 0.69 | 6207.00% | — | 2023.00% | -8.81% | -3.64 | 1269.60% | 0.00% | 0.00% | 0.46% | -6.36 | -8.56 | — | 19.07 |
About Harrow Health, Inc.
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
- CEO
- Mark L. Baum
- Employees
- 382
- Beta
- 0.10
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($241.66 ÷ $40.90) − 1 = +490.86% (DCF, example).